NasdaqGM:GHRSPharmaceuticals
GH Research (GHRS) Stock Valuation After Positive Phase 2a Mebufotenin Data In Postpartum Depression
GH Research (NasdaqGM:GHRS) put fresh clinical data in front of investors with full Phase 2a results for inhaled GH001 in postpartum depression, along with new oral presentations accepted for the CINP 2026 congress.
See our latest analysis for GH Research.
The stock has eased over the past month despite the latest clinical update, with a 30 day share price return of about 1% lower. However, momentum over longer periods remains strong, including a 90 day share price return of 39.77% and a 1...